Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants
Summary
The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the cannabis plant formulated for oral consumption, in healthy adults. The study will utilize a within-subjects, placebo-controlled, double-blind, ascending-dose design.Upon enrollment, participants will complete 5 oral dosing conditions (placebo, 25, 50, 100, and 200 mg CBG). Each condition will consist of a single acute drug exposure, followed by an 8-hour period to evaluate acute pharmacodynamic and pharmacokinetic drug effects. This work will provide novel data on the pharmacokinetics, pharmacodynamic effects, and safety of acute oral CBG dose administration in humans.
Timeline
- Start
- 2022-08-09
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabigerol | Small molecule | 25 mg | Oral |
| Subject | Cannabigerol | Small molecule | 50 mg | Oral |
| Subject | Cannabigerol | Small molecule | 100 mg | Oral |
| Subject | Cannabigerol | Small molecule | 200 mg | Oral |
Indications
No indication recorded.